Ticker brief
AMLX
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
5
authors 14d
5
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-23 → 2026-06-28 · now +0.50 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @MartyChargin | C | -0.72 | 1 | +0.10 |
| @OzmosiHealth | C | · | 1 | +0.15 |
| @Quantumup1 | C | -1.95 | 1 | +0.65 |
| @semodough | C | -0.75 | 1 | +0.60 |
| @JaguarAnalytics | B | +0.01 | 1 | +0.50 |
Recent signals5of 5 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-06-28 | @JaguarAnalytics | +0.50 | EU guideline mention and Japan cases suggest under-modeled uptake. | · | tweet ↗ |
| 2026-06-27 | @semodough | +0.60 | Guggenheim reinforces AMLX as 2026 best idea with confidence in LUCIDITY and 160k PBH target population. | · | tweet ↗ |
| 2026-06-25 | @Quantumup1 | +0.65 | Guggenheim raised AMLX PT to $40 from $30 and elevated it to Best Idea. | · | tweet ↗ |
| 2026-06-23 | @OzmosiHealth | +0.15 | Amylyx to present Phase 1 LUMINA data at ENCALS 2026. | · | tweet ↗ |
| 2026-06-23 | @MartyChargin | +0.10 | Amylyx announces presentation of Phase 1 LUMINA trial data at ENCALS 2026. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.